Funder
National Key Research and Development Program of China
Reference56 articles.
1. Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: a retrospective cohort study;Scoccimarro;Diabetes Metab Res Rev,2023
2. Empagliflozin in the treatment of type 2 diabetes: evidence to date;Shubrook;Drug Des Dev Ther,2015
3. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial;Chatur;Eur J Heart Fail,2023
4. Role of glycosuria in SGLT2 inhibitor-induced cardio-renal protection: a mechanistic analysis of the CREDENCE trial;Ferrannini;Diabetes,2023
5. The effects of sodium-glucose cotransporter 2 inhibitors beyond the cardio-renal-metabolic spectrum: will gliflozins have a different fate than statins?;Koufakis;Expet Opin Pharmacother,2023